All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Supernus Pharmaceuticals Inc. plans to acquire Biscayne Neurotherapeutics Inc. and its phase I candidate, BIS-001, in a bid to expand its neurology pipeline.
